
|Articles|March 1, 2003
Steroid Sparing
Baltimore -- The immunosuppressant agent mycophenolate mofetil (CellCept) should be considered the steroid-sparing drug of choice in the management of pemphigus, according to Daniel Mimouni, M.D.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
2
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
3
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
4
Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis
5














